Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Again Of Rare Cancer Associated With TNF Blockers

Executive Summary

FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.
Advertisement

Related Content

FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma
FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis
Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee
Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Anti-TNFs’ Link To Cancer In Children Under Investigation By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS053352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel